Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

Blood

Volumn 99, Issue 4, 2002, Pages 1159-1164

  Reusser, Pierre ^{a,b,c,d,e,f,g,h,i,j,k}   Einsele, Hermann ^{a,b,c,d,e,f,g,h,i,j}   Lee, John ^{a,b,c,d,e,f,g,h,i,j}   Volin, Liisa ^{a,b,c,d,e,f,g,h,i,j}   Rovira, Montserrat ^{a,b,c,d,e,f,g,h,i,j}   Engelhard, Dan ^{a,b,c,d,e,f,g,h,i,j}   Finke, Jürgen ^{a,b,c,d,e,f,g,h,i,j}   Cordonnier, Catherine ^{a,b,c,d,e,f,g,h,i,j}   Link, Hartmut ^{a,b,c,d,e,f,g,h,i,j}   Ljungman, Per ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Westpfalz Klinikum GmbH   (Germany)

^e Astra Arcus AB   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF HELSINKI   (Finland)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j HENRI MONDOR HOSPITAL   (France)

^k Hopital Regional   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MULTICENTER STUDY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION; SURVIVAL; THROMBOCYTOPENIA;

EID: 0037082453     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1159     Document Type: Article

References (33)

1. Risk factors for cytomegalovirus infection after human marrow transplantation
2. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy
3. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989
4. Management of viral infections
5. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
6. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
7. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial
8. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation
9. Prevention of cytomegalovirus disease after allogeneic marrow transplantation by early treatment with ganciclovir
10. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
11. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
12. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
13. Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
14. Ganciclovir
15. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
16. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis
17. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
18. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
19. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients
20. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): A dose-finding study
21. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoletic stem cell transplantation (HSCT): A randomised study
22. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
23. Definitions of cytomegalovirus infection and disease
24. A multiple testing procedure for clinical trials
25. Nonparametric estimation from incomplete observations
26. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
27. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma
28. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
29. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
30. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
31. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease
32. Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays
33. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir